EPS for Adamis Pharmaceuticals (ADMP) Expected At $-0.15; Profile of 5 Analysts Covering Calithera Biosciences, Inc. (CALA)

February 23, 2018 - By Vivian Currie

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Calithera Biosciences had 10 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright on Thursday, January 5 with “Buy”. H.C. Wainwright maintained Calithera Biosciences, Inc. (NASDAQ:CALA) on Tuesday, March 28 with “Buy” rating. On Tuesday, October 25 the stock rating was initiated by Citigroup with “Sell”. The rating was initiated by Citigroup with “Buy” on Friday, July 24. The company was maintained on Wednesday, March 9 by JMP Securities. As per Monday, June 12, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating given on Friday, February 16 by Citigroup. The company was upgraded on Tuesday, January 24 by Citigroup. See Calithera Biosciences, Inc. (NASDAQ:CALA) latest ratings:

16/02/2018 Broker: Citigroup Rating: Buy New Target: $14.0 Upgrade
05/10/2017 Broker: William Blair Rating: Outperform Initiates Coverage On

Analysts expect Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) to report $-0.15 EPS on March, 29. The stock decreased 9.73% or $0.28 during the last trading session, reaching $2.55. About 1.97 million shares traded or 174.01% up from the average. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has declined 52.09% since February 23, 2017 and is downtrending. It has underperformed by 68.79% the S&P500.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $85.14 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Among 4 analysts covering Adamis Pharma (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharma had 9 analyst reports since December 1, 2015 according to SRatingsIntel. The rating was initiated by Raymond James on Tuesday, September 12 with “Buy”. The stock of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) earned “Buy” rating by Maxim Group on Monday, June 12. Maxim Group initiated the stock with “Buy” rating in Tuesday, December 1 report. Raymond James maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rating on Monday, December 4. Raymond James has “Buy” rating and $7.0 target. The firm has “Buy” rating given on Monday, August 21 by Maxim Group. The stock has “Buy” rating by Maxim Group on Thursday, July 21.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $285.59 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize SymbioscienceÂ’s portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Investors sentiment decreased to 1.22 in 2017 Q3. Its down 2.03, from 3.25 in 2017Q2. It is negative, as 16 investors sold Calithera Biosciences, Inc. shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported. Connor Clark Lunn Invest Management has 11,620 shares for 0% of their portfolio. Blackrock Incorporated reported 2.10 million shares or 0% of all its holdings. Franklin Street Advsr Nc has invested 0.09% in Calithera Biosciences, Inc. (NASDAQ:CALA). Amer Group reported 20,536 shares. Wells Fargo & Mn stated it has 33,742 shares. California Employees Retirement reported 43,719 shares. Ascend Capital Ltd Liability Co invested in 0.39% or 658,195 shares. Citadel Advsrs Ltd Co stated it has 480,673 shares or 0.01% of all its holdings. Pacad Invest invested 0.03% in Calithera Biosciences, Inc. (NASDAQ:CALA). Meeder Asset reported 0% stake. Viking Global Invsts L P has invested 0.27% in Calithera Biosciences, Inc. (NASDAQ:CALA). 57,938 are held by Citigroup. 175,000 were accumulated by Artal Gp. Dupont Capital accumulated 16,394 shares. Macquarie Limited holds 4,600 shares or 0% of its portfolio.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.